Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$54.3 million.

  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders fell 2070.05% to -$54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.7 million, marking a year-over-year increase of 2440.45%. This contributed to the annual value of -$264.6 million for FY2024, which is 4326.12% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Net Income towards Common Stockholders is -$54.3 million, which was down 2070.05% from -$48.0 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $43.8 million during Q1 2021, with a 5-year trough of -$141.4 million in Q1 2024.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$44.9 million (2022), whereas its average is -$45.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 22805.88% in 2021, then crashed by 22007.09% in 2022.
  • Rhythm Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then dropped by 7.2% to -$44.6 million in 2024, then dropped by 21.62% to -$54.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$54.3 million for Q3 2025, versus -$48.0 million for Q2 2025 and -$50.8 million for Q1 2025.